Pharmaceuticals & Biotech Danish Community

Novo Nordisk’s business model is straightforward. It develops hormone-based therapies, protects them with patents, manufactures them at scale, and sells them at high margins into reimbursed healthcare systems.Read more

Cash Source Summary Their revenue has had a significant upwards trajectory growing 10%+ since FY21, with these trailing twelve months growing at ~17%. This growth is not there to a degree that is unsustainable, as 10%-30% growth can be achieved over time, and their proven track record is an even better sign of success.Read more

31 Dec 2025 For shareholders of Novo Nordisk (NVO) , the past three years have been a masterclass in value creation. High margins, infinite demand, and a virtual monopoly in the obesity market drove the stock to record highs.Read more

Business Overview Total: 8.5/17 +2 ✅✅ Projected Operating Margin: 43.88% +1 ✅ Projected 5-Year Revenue CAGR: 11.93% +2 ✅✅ Last 5-Year ROIC: 54.60% +1 ✅ Estimated Cost of Capital: 7.54% (lower than ROIC) +1 ✅ Last 5-Year Shares Outstanding CAGR: -0.89% -1 ❌ Projected 5-Year EPS CAGR: 8.49% (given the easiness that the companies have in manipulating these numbers, below 10% represents a negative) +0 ⚠️ Projected 5-Year Dividend CAGR: 6.45% +1.5 ✅ Estimated Debt Rating: Aa3 +2 ✅✅ Morningstar Moat: Wide -1 ❌ Morningstar Uncertainty: High Novo Nordisk is the leader in obesity and diabetes treatments. Its wide moat is reflected on its stellar operating margin.Read more

Novo Nordisk, one of the world’s leading pharmaceutical companies, has a unique and inspiring origin story rooted in personal tragedy and scientific curiosity. The company’s roots date back to the 1920s, when Danish Nobel laureate August Krogh, a renowned physiologist, and his wife Marie, who suffered from type 2 diabetes, traveled to Canada.Read more

Catalysts Most Immediate Catalyst (1–2 Years): Weight-Loss Drug Boom: Novo Nordisk’s Wegovy (semaglutide) is dominating the obesity drug market , with demand outpacing supply. Obesity treatment is becoming a major new revenue stream.Read more

Gubra sits at the crossroads of outsourced biotech research and early-stage drug discovery, and its growing pipeline and big pharma partnerships could make it less dependent on day-to-day lab service work. But biotech funding swings, uneven partnership payments, and new tech that could replace animal testing may all test how steady its growth can really be.Read more

Genmab is pushing beyond its royalty roots with new cancer medicines and a deep late-stage pipeline, aiming to grow sales globally through more of its own launches. The upside comes with real hurdles, from drug pricing pressure and heavy reliance on a key partner product to regulatory delays and tough competition in fast-moving cancer treatments.Read more

Lundbeck’s brain and mental health medicines face a squeeze as governments push harder on drug pricing and safety rules, just as newer, more targeted treatments could shift doctors and patients away from older therapies. With several key products aging and more competition on the way, the question is whether its newer brands and research pipeline can keep growth on track.Read more